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Reports of toxic effects on the kidney of lithium treatment emerged very soon after lithium therapy was introduced.
Lithium-induced nephrogenic diabetes insipidus is usually self-limiting or not clinically dangerous. Some reports of
irreversible chronic kidney disease and renal failure were difficult to attribute to lithium treatment since chronic
kidney disease and renal failure exist in the population at large. In recent years, large-scale epidemiological studies
have convincingly shown that lithium treatment elevates the risk of chronic kidney disease and renal failure. Most
patients do not experience renal side effects. The most common side effect of polyuria only weakly predicts increasing
creatinine or reduced kidney function. Among those patients who do experience decrease in creatinine clearance,
some may require continuation of lithium treatment even as their creatinine increases. Other patients may be able to
switch to a different mood stabilizer medication, but kidney function may continue to deteriorate even after lithium
cessation. Most, but not all, evidence today recommends using a lower lithium plasma level target for long-term
maintenance and thereby reducing risks of severe nephrotoxicity.
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Lithium is a useful mood stabilizer for maintenance
treatment of bipolar disorder (Belmaker 2004; Gershon
et al. 2009). It has established antimanic effect and pro-
phylactic efficacy against recurrence of affective episodes
(Belmaker 2004; Gershon et al. 2009). Another advan-
tage of lithium is its proven ability to reduce suicide at-
tempts and suicidal death among bipolar patients. In
recent years, concern has developed about the risk of
lithium therapy in rare cases leading to chronic renal
failure and even necessitating kidney dialysis. In this
paper, we discuss these concerns about lithium therapy
even as we hope that lithium with its unique clinical
benefits will be used more widely in psychiatry. Experi-
ence in psychiatry with the late recognition of the ser-
ious metabolic side effects of atypical antipsychotics
leads us to believe that it is better to confront concerns
about this serious side effect now, rather than allowing
the issue to polarize into a situation where there are
those clinicians “for lithium” and those clinicians “against
lithium.”* Correspondence: belmaker@bgu.ac.il
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provided the original work is properly creditedKidney function impairments in patients taking lith-
ium were reported as early as the 1970s (McKnight et al.
2012; Markowitz et al. 2000; Kallner and Petterson 1995;
Bucht and Wahlin 1980; Hestbech et al. 1977; Baylis and
Heath 1978; Angrist et al. 1970). Lithium therapy has been
associated with a number of renal function abnormalities.Nephrogenic diabetes insipidus
The most common renal side effect of lithium is of con-
centrating urine despite normal or elevated concentra-
tions of the antidiuretic hormone vasopressin (Table 1).
The concentrating defect leads to decreased urine osmo-
lality and increased urine volume (polyuria). A urinary
concentrating defect may occur without overt polyuria,
but this is usually clinically insignificant because near-
normal urinary volume rarely leads to the performance
of urine osmolality tests.
The incidence of nephrogenic diabetes insipidus (NDI)
among lithium-treated patients varies greatly in different
studies, with a prevalence range of 20 to 87 % (Baylis
and Heath 1978; Vestergaard et al. 1979; Vestergaard
and Amdisen 1981; Schou and Vestergaard 1988; Okusa
and Crystal 1994; McKnight et al. 2012; Markowitz et al.
2000; Kallner and Petterson 1995; Bucht and Wahlin
1980; Boton et al. 1987). For example, in a comprehensive
meta-analysis of studies comprising 1172 lithium-treatedle distributed under the terms of the Creative Commons Attribution License
hich permits unrestricted use, distribution, and reproduction in any medium,
.
Table 1 Controversies over lithium and the kidney (selected references)
Yes No
Lithium causes anatomic kidney damage Markowitz et al. (2000) Vestergaard et al. (1979)
Low-dose lithium prevents kidney damage Aiff et al. (2014a) Close et al. (2014)
Duration of lithium treatment predicts Li polyuria Bendz et al. (2001) Lepkifker et al. (2004)
Duration of lithium predicts reduced GFR Bendz et al. (2010) Smigan et al. (1984)
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ary concentrating ability in more than 54 % of patients
while only 19 % had overt polyuria.
Many studies found that major factors affecting the in-
cidence and severity of urinary concentrating defects
among lithium-treated patients are as follows: duration
of treatment (longer duration increases the risk of NDI),
blood lithium level, and frequency of acute lithium in-
toxications (Vestergaard et al. 1979; Vestergaard and
Amdisen 1981; Schou and Vestergaard 1988; Markowitz
et al. 2000; Bucht and Wahlin 1980; Boton et al. 1987;
Walker 1993; Turan et al. 2002; Timmer and Sands
1999; Bendz et al. 2001). On the other hand, Lepkifker
et al. (2004) observed that the duration of lithium treat-
ment and plasma concentrations were not associated
with increased risk of urinary concentrating defect while
episodes of lithium intoxication were more predictive
and positively correlated. A urinary concentrating defect
may occur as early as 2 to 4 months after the com-
mencement of lithium (Boton et al. 1987; Smigan et al.
1984), but it becomes more evident after chronic treat-
ment (Vestergaard and Amdisen 1981; Markowitz et al.
2000; Bendz et al. 2001; Phillips et al. 2008). NDI may
develop even after cessation of lithium therapy (Paw
et al. 2007). Additionally, several studies demonstrated
that cessation of long-term lithium therapy does not al-
ways restore the urinary concentrating capacity of the kid-
ney (Markowitz et al. 2000; Bendz et al. 2001; Khairallah
et al. 2007) while others reported that it may alleviate the
concentrating defect (Bucht and Wahlin 1980). These var-
iations may be related to the stage of tubulointerstitial
damage at which lithium was stopped. An early stage at
which only functional tubulointerstitial damage has oc-
curred may be fully reversible. On the other hand, a late
stage at which irreversible morphological tubulointerstitial
changes (fibrosis) have occurred will not be resolved by
lithium cessation. Importantly, patients with polyuria that
do not consume sufficient amounts of fluids are at a high
risk of becoming volume-depleted, further increasing the
risk of lithium toxicity (Vestergaard et al. 1979; Vestergaard
and Amdisen 1981; Smigan et al. 1984). Furthermore, pa-
tients who were concurrently treated with lithium and
neuroleptic drugs had significantly higher rates of urinary
concentrating defects than patients who were treated only
with lithium. Consistently, antipsychotics (only)-treatedpatients had a higher incidence of urinary concentrating
defects than matched healthy subjects (Bucht and Wahlin
1980). These observations suggest that antipsychotic drugs
may contribute to the development of urinary concentrat-
ing defects.
Acute lithium treatment reduces the antidiuretic effect
of vasopressin (Singer et al. 1972). Similarly, chronic
lithium treatment was shown to reduce the antidiuretic
effect of vasopressin by several possible mechanisms.
The most established pharmacological treatment for
lithium-induced NDI is the potassium-sparing diuretic
amiloride (Boton et al. 1987; Timmer and Sands 1999;
Feuerstein et al. 1981; Bedford et al. 2008). However,
amiloride is likely to be effective only when there is a
mild to moderate urinary concentrating defect that is
potentially reversible. Among the suggested mechanisms
by which amiloride alleviates lithium-induced urinary
concentrating defect are as follows: i) blocking of epithe-
lial sodium channel ENaC, resulting in reduced absorp-
tion of lithium into collecting duct cells (Walker et al.
1982), and ii) restoring to normal the expression levels
of AQP2 and AQP3 (Bedford et al. 2008).
Chronic kidney disease
According to the American National Kidney Foundation
(2002), chronic kidney disease (CKD) is defined as either
kidney damage or GFR <60 ml/min/1.73 m2 for ≥3 months.
Kidney damage is defined as pathologic abnormalities or
markers of damage, including abnormalities in blood or
urine tests or imaging tests. The staging of CKD according
to GFR (ml/min/1.73 m2) is as follows: Stage 1—kidney
damage with normal or increased GFR (GFR ≥90); Stage
2—kidney damage with a mildly decreased GFR (GFR =
60–89); Stage 3—moderate reduction in GFR (GFR = 30–
59); Stage 4—severe reduction in GFR (GFR = 15–29); and
Stage 5—kidney failure (GFR <15 or dialysis) (American
National Kidney Foundation 2002). End-stage renal dis-
ease (ESRD) describes a situation in which patients need
dialysis or transplantation, irrespective of their level of
kidney function (American National Kidney Foundation
2002).
Early studies questioned the association between lith-
ium and chronic impairment in glomerular function
(Vestergaard et al. 1979; Vestergaard and Amdisen 1981;
Boton et al. 1987; Walker 1993; Walker et al. 1982;
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2010). In 1979, Vestergaard et al. (1979) examined renal
function among 237 patients who had been treated with
lithium for 0.5–17 years (average 5 years). They deter-
mined GFR by examining 24-h creatinine clearance and
serum creatinine. It was found that lithium treatment re-
duced GFR only slightly and that the risk of developing
ESRD was low (Bucht and Wahlin 1980). Two years
later, these authors published a follow-up report on 184
patients of the same population in which they re-
examined renal function (Vestergaard and Amdisen
1981). For 37 patients, lithium had been discontinued
while the other 147 were still on lithium. None of the pa-
tients in either group had a reduction in GFR (Vestergaard
and Amdisen 1981). Impairments in urinary concentrating
ability had however progressed in the lithium-treated
group. Subsequently, Walker et al. (1982) reported that
the results of renal biopsy samples analyzed for interstitial
fibrosis showed no difference between lithium-treated pa-
tients and those who did not receive lithium. However, ab-
normal serum creatinine levels were significantly higher in
lithium-treated patients as compared to those who did not
receive lithium, suggesting an impaired GFR (Walker et al.
1982). A meta-analysis study by Boton et al. revealed that
15 % of 1172 patients on chronic lithium therapy dis-
played only mild reduction in GFR (Timmer and Sands
1999). Bendz et al. (1983) examined glomerular function
in outpatients who received short-term and long-term
lithium treatment. They found that 3 % had abnormal
glomerular function while 51 % had impaired tubular
function. Eleven years after the previous study (Bendz
et al. 1983), they reported that among 142 patients who
received lithium for more than 15 years, a reduction in
GFR was observed in 21 % of the patients (Bendz et al.
1994). The results also revealed that co-administration of
lithium with other psychotropic drugs or somatic medica-
tions increased the risk of altered renal function. Coskunol
et al. (1997) compared 107 lithium-treated patients to 29
non-lithium-treated patients matched for age and sex.
They found that plasma creatinine levels and creatinine
clearance did not significantly differ between the two
groups. In addition, they found that there was no signifi-
cant association between creatinine clearance and the dur-
ation (or dosage) of lithium treatment (Coskunol et al.
1997). A meta-analysis of 23 studies conducted by Paul
and co-workers concluded that: “any lithium-associated
increase in serum creatinine is quantitatively small and of
questionable clinical significance;” this is despite a signifi-
cant increase in serum creatinine levels in several studies
that were analyzed (Paul et al. 2010). A comprehensive
meta-analysis of 385 studies by McKnight et al. (2012)
found a non-significant (p = 0.15) reduction in GFR and a
low risk for developing ESRD among lithium-treated
patients.Despite the uncertainty reported in the studies cited
above, other studies have suggested that long-term lith-
ium therapy increases the risk of CKD (Markowitz et al.
2000; Turan et al. 2002; Bendz et al. 2001, 2010; Aiff
et al. 2014a; Kripalani et al. 2009; McCann et al. 2008;
Presne et al. 2003). One of the studies that demonstrated
deleterious and mostly irreversible renal damage after
chronic lithium therapy was that by Markowitz et al.
(2000), which included 24 patients (average lithium
treatment duration 13.6 years) with renal insufficiency.
Renal biopsy results revealed a chronic tubulointerstitial
nephropathy in all patients, with associated cortical and
medullary tubular cysts and dilation in 62.5 and 33.3 %
of patients, respectively (Markowitz et al. 2000). Nine of
19 patients progressed to ESRD despite lithium with-
drawal (eight of nine had an initial serum creatinine
above 2.5 mg/dL and one of ten had an initial serum
creatinine below 2.5 mg/dL). On the other hand, three
patients with initial creatinine levels below 2.1 mg/dL had
subsequent improvement in renal function (Markowitz
et al. 2000). The authors concluded that serum creatinine
levels higher than 2.5 mg/dL are the only significant pre-
dictor of progressing to ESRD.
The Markowitz et al. (2000) study was retrospective,
biopsy-based from a selected renal biopsy database. Of
6514 biopsies that made up the database, only 24
(0.37 %) were those of lithium-treated patients. More-
over, it is not clear whether lithium therapy was indeed
the sole reason for kidney disease and referral to renal
biopsy. One of the patients who discontinued lithium
subsequently committed suicide, underscoring the com-
plexity of discontinuing lithium even in the presence of
kidney disease. A study by Presne et al. (2003) also dem-
onstrated the correlation between long-term lithium
therapy and CKD. It included 54 patients for whom
chronic lithium treatment was apparently the only cause
of renal disease (during the study period, six other pa-
tients were excluded because they had evidence of other
causes for renal disease). Another 20 patients on chronic
lithium therapy were referred for systematic renal bi-
opsy. Among those 74 patients (mean age at onset of
lithium therapy 42.9 years, mean duration of lithium
therapy 19.8 years), 12 (16%) reached ESRD at a mean
age of 65 years (Presne et al. 2003). Renal function was
determined by measuring serum creatinine and creatin-
ine clearance. Lithium-induced chronic nephropathy
seemed to be a slowly progressing disease. The average
latency between initiation of lithium and the progression
to ESRD was estimated at 20 years (Presne et al. 2003).
The severity of interstitial fibrosis on renal biopsy was
associated with treatment duration and cumulative dose
of lithium.
A survey of lithium-induced ESRD in French dialysis
centers was conducted. Among 10,726 patients surveyed,
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et al. 2003). The authors found that the duration of lith-
ium treatment is the most significant factor that nega-
tively affects renal function. A cohort study of kidney
damage in long-term lithium patients demonstrated a
significant correlation between treatment duration and
the frequency of decreased GFR and urinary concentrat-
ing ability (Bendz et al. 2001). Eighty-six patients were
on lithium (mean age 58, mean treatment duration
16 years) and 42 patients (mean age 57, mean treatment
duration 10 years) were off lithium at follow-up time.
For lithium-treated patients, the frequency of reduced
urinary concentrating ability and increased serum cre-
atinine significantly increased during mean follow-up pe-
riods of 8 and 10 years, respectively (Bendz et al. 2001).
The authors concluded that among patients on long-
term lithium therapy, the prevalence of significant ne-
phropathy increases with time and that reduced GFR is
less common than a reduction in urinary concentrating
ability (Bendz et al. 2001). Similarly, a study by McCann
et al. (2008) examined 38 patients who had been treated
with lithium for a mean of 6.9 years (short-term) and 21
patients who were on lithium for a mean of 14.2 years
(long-term). They found that long-term treatment pa-
tients had a significantly higher serum creatinine and
urea levels (McCann et al. 2008). However, this study
had several limitations including the relatively small
sample size and being a retrospective, cross-sectional
study. These and other limitations led the authors to
emphasize that although “regression analysis does show
that longer duration of lithium use is associated with
higher creatinine level,…, this is not necessarily associ-
ated with a clinically relevant abnormalities in renal
function” (McCann et al. 2008).
Bendz et al. (2010) assessed the prevalence of ESRD
that required renal replacement therapy (RRT) in a
lithium-treated population in Sweden. They found that
2202 subjects were on RRT among the surveyed general
population (2,684,157), a prevalence of 0.8/1000. On the
other hand, among a population of 3369 lithium-treated
patients, 18 were on RRT (5.3/1000), representing a six-
fold increase in RRT prevalence (Bendz et al. 2010). For
the latter 18 patients on RRT, lithium treatment was ap-
parently the only reason for ESRD (lithium-treated pa-
tients on RTT were excluded if they had other reasons
that may have caused ESRD). The average age at the
start of RRT among those 18 patients was 62 years
(range 46–74), and the average duration of lithium treat-
ment before initiation of RTT was 23 years (range 12–
35). Moreover, of the 3369 lithium-treated patients, 41
had plasma creatinine levels above 150 μmol/L (not in-
cluding RRT patients), a prevalence of 12.2/1000. The
authors concluded that the duration of lithium therapy
was the only risk factor for developing CKD and ESRD.Long-term treatment was defined as a duration of
≥15 years on lithium. It was found that 16 (89 %) of the
lithium-treated RTT patients had received lithium for
more than 15 years. Similarly, lithium-treated patients
who had plasma creatinine levels above 150 μmol/L were
older than the general population of lithium-treated pa-
tients (average age 68 versus 56 years, respectively). The
results of this retrospective study (Bendz et al. 2010) sup-
port a positive correlation between long-term lithium
therapy and development of CKD (Aiff et al. 2014b).
Reduced GFR may sometimes occur at early stages
after initiation of lithium therapy. For example, a prom-
inent reduction in GFR was found among 53 patients
who received lithium for only 4 months (Smigan et al.
1984). Lepkifker et al. (2004) studied 114 patients who
had been taking lithium for 4 to 30 (mean 16.75) years.
The control group included 94 untreated non-psychiatric
subjects matched for sex and age (mean duration of
follow-up 11.9 years). Ninety lithium-treated patients
(79%) showed no increase in creatinine levels during a
follow-up of up to 30 years and were similar to the control
group. The other 24 patients had a progressive increase in
creatinine levels during the follow-up period and were
classified as having renal insufficiency (Lepkifker et al.
2004). The development of renal insufficiency was associ-
ated with episodes of lithium intoxication, other diseases,
and/or drugs that affect renal function but not with the
duration of lithium treatment in a majority of patients
(Lepkifker et al. 2004).
The above reviewed evidence seems contradictory and
difficult to summarize. Aiff et al. (2014a) suggested a po-
tential solution to the contradictions: They found using
their large Swedish registry that no patient treated since
1980 has developed ESRD in their sample and concluded
that low-dose treatment apparently in use since then in
Sweden does not cause ESRD. This is supported by the
results of Aprhamian et al. (2014) who found no changes
in kidney function after 2 years of low-dose lithium in
elderly patients. However, Close et al. (2014) did not find
this “time of treatment” effect in the UK in their large
registry study. This “historical” approach does not ex-
plain the very early studies that found no effects of lith-
ium in kidney biopsy. A general recommendation to use
low-dose lithium, while consistent with the medical
principle of primum non nocere and medical caution,
does not help the clinician with difficult patients who re-
spond fully only to high-dose maintenance. High-dose
lithium has been reported to have increased efficacy in
both prophylaxis and bipolar depression. Clearly, indi-
vidual patient history of response and severity of epi-
sodes must be critical in the decision-making (Belmaker
et al. 2012).
In summary, the evidence attests to a small but definite
risk of lithium-induced reduction in GFR and progression
Azab et al. International Journal of Bipolar Disorders  (2015) 3:13 Page 5 of 9to CKD. Some studies indicate that the risk for CKD and
ESRD is low while others suggest that long-term lithium
treatment increases the risk for chronic nephropathy to a
clinically relevant degree.
Case histories
Three of the authors (RHB, YB, YO) have maintained a
bipolar clinic including lithium therapy for over 30 years
servicing a defined catchment area of 300,000 people in
southern Israel (Osher et al. 2010). We reviewed our
charts for evidence of patients who had developed kid-
ney disease:
1. ST (female, 65 years old). The patient was started on
1500 mg/day lithium at age 34 following
hospitalization for acute mania. She was stable for
13 years. After the appearance of polyuria, the dose
was reduced to 900 mg/day. Five years later,
following a depression and reinstatement of
1500 mg/day, blood level rose to 1.8 mEq/L and
creatinine levels reached 1.8 mg/dL. Nephrology
consultation diagnosed mild renal failure, and the
patient was switched gradually to valproate (800 mg/
day); after which, no further progression of kidney
damage was observed. Nine years after complete
cessation of lithium, however, creatinine rose to
3.5 mg/dL and the patient began dialysis treatment 3
years ago. She is currently stable on valproate,
awaiting a kidney transplant.
2. OE (male, 38 years old). The patient was first
hospitalized at age 25 with a severe psychotic mania.
Symptoms proved very difficult to control without
high doses of lithium (up to 2550 mg/day) plus
valproate and dopamine blockers (olanzapine or
clozapine). Patient relapsed with psychotic
symptoms any time blood lithium levels fell below
1.2 mEq/L. Creatinine levels rose from 1.1 to
1.4 mg/dL and blood urea nitrogen (BUN) from 27
to 43 mg/dL over a period of a few months. Lithium
dose was lowered to 1500 mg/day, but the kidneys
continued to deteriorate. Additional decreases of
lithium dosage were postponed due to the objections
of the patient and family. Recently, after the
introduction of asenapine 30 mg/day in addition to
olanzapine 10 mg and valproate 2500 mg/day,
lithium has been reduced to 600 mg/day. Creatinine
levels are currently 1.5 mg/dL, BUN = 53 mg/dL,
and the patient is reasonably stable.
3. MBD (female, 77 years old). First hospitalized with
severe depression at age 28, this patient began
treatment with lithium (plus clomipramine) after a
second hospitalization at age 50. She was stable for
many years on lithium 900 mg/day, with blood levels
of 0.5–0.6 mEq/L. Rheumatoid arthritis developedand was treated with azathioprine or gold; during
the 6 years she received this treatment, lithium
dosage was raised to 1200 mg/day and blood levels
ranged from 0.6 to 1.2 mEq/L. The dosage was
subsequently returned to 900 mg/day. Parkinson’s
disease developed and was treated with rasagiline,
carbidopa, and levodopa. When creatinine levels of
2.07–3.2 mg/dL and BUN of 66 mg/dL were
observed, lithium was reduced to 150 mg/day.
Creatinine and BUN levels began to improve.
Shortly thereafter, at age 77, the patient left the area
and was lost to follow-up.
4. JL (female, 60 years old). First hospitalized at age 32
due to a manic psychosis, this patient had an
additional hospitalization less than a year later.
Lithium was started at age 34, and the patient had
full remissions (with four hospitalizations) for 17
years. When hospitalized again at age 51, lithium
treatment was stopped (due to “lack of efficacy”) and
treatment was switched to valproic acid plus
perphenazine and afterwards continued as
perphenazine alone. After 5 years of fragile stability
and several mood episodes which did not require
hospitalization, the patient was hospitalized again at
age 56 and lithium was reinstated at a low dose
(600 mg/day) plus 4 mg perphenazine. One year
later, creatinine rose above 1.0 mg/dL. The patient
has been affectively stable for the past 4 years, and
creatinine is currently 1.5 mg/dL.
5. DL (female, 37 years old). While in her early 20s,
this patient experienced major depression and
attempted suicide. She was treated with valproate
plus fluoxetine, which precipitated a manic episode
and hospitalization. After 2 years of failed attempts
at stabilization with valproate plus haloperidol or
ziprasidone, including substantial weight gain, the
patient was switched to lithium plus risperidone. A
miscarriage and subsequent depression was treated
with lithium 2100 mg/day plus perphenazine, with
lithium blood levels reaching 1.5 mEq/L. The patient
went through a successful pregnancy and delivery
while being managed on lithium, but after 3 years,
she developed nephrogenic diabetes insipidus. She
was gradually switched over to lamotrigine (400 mg/
day) plus perphenazine 8 mg/day and has been
reasonably stable for 4 years, with creatinine levels
of 1.0 mg/dL.
6. SD (male, 47 years old). The patient began
treatment with carbamazepine plus haloperidol after
a severe psychotic episode at age 25. After several
additional hospitalizations in quick succession,
lithium was added to the treatment, at first 1800–
2100 mg/day then later reduced to 900 mg/day.
Initial creatinine level was measured at 1.0 mg/dL
Azab et al. International Journal of Bipolar Disorders  (2015) 3:13 Page 6 of 9but rose to 2.5–2.7 mg/dL after being on lithium for
10 years. Nephrogenic diabetes insipidus and renal
failure developed during a 3-month period in which
the patient was lost to follow-up. Lithium treatment
was stopped; carbamazepine was continued. Patient
was again lost to follow-up for 1 year, and at the end
of which, he was hospitalized and diagnosed with
end-stage renal failure (creatinine = 7.2 mg/dL).
Treatment was changed to chlorpromazine, and the
patient began renal dialysis and subsequently
underwent a kidney transplant, which failed after 1
year. He is currently stable on chlorpromazine plus
diazepam and is wait-listed for a second kidney
transplant.
7. RP (male, 64 years old). Hypomanic episodes were
experienced along with numerous hospitalizations
for depression between the ages of 23 and 53. The
patient was treated with a variety of medications and
interventions not including lithium. Prior to
hospitalization resulting from a suicide attempt at
age 53, the patient had been treated with
carbamazepine plus clonazepam. During the
hospitalization, treatment was changed to lithium
(1200 mg/d). The patient was stable for 8 years, but
when creatinine level rose to 1.88 mg/dL and BUN
to 42 mg/dL, lithium was reduced to 600 mg/day
and then discontinued in favor of a combination of
valproate and carbamazepine. He has been
reasonably stable on this combination for
approximately 3 years. Creatinine level has reduced
slightly (currently 1.55 mg/dL) and BUN is currently
36 mg/dL.
8. SP (male, 66 years old). The patient’s first affective
episode, at age 18, included a switch from
depression to mania and a suicide attempt. He was
treated with lithium and thioridazine for 29 years,
with a full remission and only one additional
hospitalization, until developing nephrogenic
diabetes insipidus. Lithium was stopped and
treatment switched to valproic acid plus topiramate
and risperidone. The patient could not be stabilized,
although multiple agents were tried, and
experienced six hospitalizations during the following
5 years. Lithium was reinstated (900 mg/day) when
the patient was 56 years old. One year later,
creatinine was 1.59 mg/dL but rose quickly to
2.3 mg/dL within a few months. Lithium dose was
reduced to between 600 and 750 mg/day, with blood
levels of 0.9–1.1 mEq/L, and patient was stable with
only one brief hospitalization over a period of 7
years. At that time, with creatinine at 2.06 mg/dL
and lithium blood levels of 0.85 mEq/L although the
dose had been reduced to 300 mg/day, it was
decided again to stop lithium. The patient becameseverely manic within a few months in spite of
treatment with relatively high doses of atypical
antipsychotic medication, requiring hospitalization.
Lithium was reinstated at doses of 300–600 mg/day,
and the patient has remained reasonably stable for 3
years. Creatinine levels have continued to increase
to 2.8 mg/dL and BUN 83 mg/dL, and the patient is
currently being followed by a nephrologist while
continuing treatment with lithium at low doses plus
olanzapine.
9. SH (female, 66 years old). This patient, with a strong
family history for bipolar disorder, experienced a
psychotic postpartum depression at age 20 and
began lithium prophylaxis following a successful
course of electroconvulsive therapy. Lithium was
continued with good remissions (though some
recurrent affective episodes and hospitalizations).
Hypothyroidism and parathyroid adenoma were
treated by an endocrinologist without the need to
stop lithium; the patient also had surgery for a
cancerous growth in her breast. After 39 years of
lithium treatment, the patient developed renal
insufficiency with creatinine clearance of 50 ml/min,
creatinine level = 1.6 mg/dL. She was successfully
switched over to valproate (800 mg/day)
approximately 5 years ago. She has been stable, with
valproate levels in the 80s; creatinine is currently
2.0–2.2 mg/dL and BUN = 65 mg/dL.
10. LR (male, 54 years old). First hospitalized for an
acute psychotic episode at age 17, this patient
experienced multiple hospitalizations over a period
of 7 years until lithium was added to his treatment.
He remained essentially stable for 28 years while
being treated with a combination of lithium
1500 mg/day plus chlorpromazine. Complications
of treatment occurred over time, including
hypertension and hyperthyroidism, and at age 52,
he was diagnosed with chronic renal failure
(creatinine = 1.62 mg/dL, BUN = 44 mg/dL). The
patient was switched to treatment with valproate
2000 mg/d plus risperidone 3 mg/day and is
currently stable with creatinine level of 1.75 mg/dL.
11. RB (male, 68 years old). Although known to have a
“bad temper” and a positive family history for
affective disorder, this patient was not diagnosed as
having bipolar disorder until a first hospitalization
for mania at age 50. He was stabilized on lithium
1500 mg/day plus low doses of various dopamine
blockers. Lithium dosage was reduced to 600 mg/
day when blood levels reached 1.4 mEq/L;
creatinine clearance at the time was 70 mL/min,
creatinine = 1.4 mg/dL, and BUN = 47 mg/dL.
Stopping lithium was discussed, but due to a
difficult bereavement, it was decided to continue
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year on lithium 300 mg/day plus risperidone 2 mg/
day, with slight reduction in creatinine level (to
1.23 mg/dL) and BUN unchanged at 48 mg/dL.
12. YA (male, 66 years old). Although pronounced
episodes of depression and hypomania were evident
from the age of 33, with severe effects on his
occupational and personal life, this patient was first
diagnosed with bipolar disorder during his first
hospitalization, at age 41 (for mania). He began
treatment with 1200 mg/day lithium and was stable
for 9 years. Due to inconsistent adherence,
valproate was added at that point and lithium
reduced to 900 mg/day. Lithium was reduced to
600 mg/day when creatinine level rose to 1.2 mg/dL
(BUN = 34 mg/dL) and polyuria appeared. The
patient became unstable when attempts were made
to further lower lithium dose, until olanzapine
(5 mg/day) was added to the treatment. One year
later, the patient developed diabetes mellitus.
Creatinine rose slightly (to 1.3 mg/dL, BUN= 34 mg/
dL), and lithium was reduced to 300 and finally to
150 mg/day (the patient is extremely reluctant to
stop lithium entirely). Although affectively stable, the
patient has developed early-onset dementia,
apparently due to cerebral aneurysm.
13. MO (male, 52 years old). Two years after a first
hospitalization for psychotic mania at age 24, this
patient with a positive family history of affective
disorder began treatment with lithium. At age 43,
he attempted suicide by ingesting 33 lithium tablets;
creatinine level at that time was 1.4 mg/dL and
BUN 34 mg/dL. Two years later, the patient again
attempted suicide by ingestion of 55 lithium tablets.
Lithium treatment was then terminated due to
renal failure (creatinine = 1.8 mg/dL, BUN = 49 mg/
dL), and the patient was switched over to clozapine.
Creatinine and BUN levels continued to rise despite
the cessation of lithium. In addition to chronic
renal failure due to lithium poisoning, the patient
also suffers from hyperthyroidism, hypercalcemia,
dyslipidemia, and hypertension.
14. GG (male, 35 years old). Although apparently ill
from his teens, this patient was first hospitalized
and diagnosed with bipolar illness at age 26. He was
eventually stabilized on lithium 1500 mg/day (blood
levels 1.1–1.2 mEq/L) plus clozapine. Creatinine
began to rise to 1.5 mg/dL, and lithium dosage was
reduced to 900 mg/day and then stopped gradually
over a period of 6 months. The patient is currently
stable on clozapine, and creatinine is currently
1.3 mg/dL and BUN 24 mg/dL.
15. VV (female, 78 years old). This patient, with a
strong family history of bipolar disorder, was firstdiagnosed (with mania) at age 58. For the following
17 years, she was treated with lithium (750–900 mg/
day; blood lithium levels approximately 0.75 mEq/L).
At age 75, she developed chronic renal failure, with
creatinine = 1.4 mg/dL and BUN= 44 mg/dL. She
continues to be treated with lithium at low doses
(300–450 mg/day), with blood lithium levels 0.8–
1.0 mg/day, and is affectively stable. Creatinine is
currently 1.6 mg/dL and BUN = 62 mg/dL.
In summary, out of approximately 180 active patients
currently in our affective disorders clinic, we have 2 pa-
tients on dialysis and another 13 with identified renal
disorder. Over 90% of our patients have been exposed to
lithium therapy at some point in time, although only
roughly 60% are currently being treated with lithium, ei-
ther as monotherapy or in combination with other medi-
cations. This translates to a very rough renal dysfunction
prevalence of 7–8 %, similar to that reported by Close
et al. (2014). However, the analysis of Close et al. (2014)
suggests that one half to two thirds of this prevalence is
caused in reality by factors other than lithium (Werneke
and Ott 2014).
Conclusions
Since chronic kidney disease exists in the population
with many etiologies and its incidence increases with
age, it was denied for many years that lithium is a spe-
cific cause of chronic kidney disease. The accumulated
epidemiologic, biologic, and clinical evidence today
weighs in favor of the concept that lithium does increase
the risk for chronic kidney disease. The course of this ef-
fect is not clear. Some patients have slow increases in
creatinine late in life and can be maintained on lithium
on lower doses while other patients have severe in-
creases in creatinine with decreases in kidney function
that are progressive even after lithium is discontinued.
The atypical antipsychotics that have been promoted as
safe alternatives to lithium in the treatment of bipolar
disorder have been revealed in many cases to have
short-term effects on glucose and lipids and long-term
risks of diabetes, side effects no less serious than the
chronic kidney disease associated with lithium. On the
other hand, some clinicians find lithium treatment
uniquely useful and effective and deny or ignore the risk
of chronic kidney disease. Clearly, there is no free lunch
in pharmacological treatment of medical disorders.
Short-term and long-term side effects are correlated al-
though not entirely. Just as weight gain and hyperlipid-
emia predict the risk of diabetes after long-term
quetiapine treatment but not so well as to eliminate the
risk in a quetiapine patient without weight gain, thus,
nephrogenic diabetes insipidus and episodes of lithium
intoxication may partially predict long-term development
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factors does not eliminate the risk. In general, the use of
higher lithium doses in the past may be responsible for
much of the lithium toxicity reported even now in epi-
demiological studies. It is best to use the lowest blood
level effective in each particular patient (American
National Kidney Foundation 2002).
For some patients with bipolar disorder who have
lithium-responsive bipolar patients in the family, lithium
is an absolute first choice of treatment. Other patients
will receive lithium because of the side effects with anti-
convulsants or atypical antipsychotics or lack of efficacy
with those compounds. Chronic kidney disease may
occur in such patients and its risks minimized by appro-
priate clinical monitoring. There is no specific biopsy
finding that at present would allow us to definitively
ascribe those cases that do develop chronic kidney
disease to the lithium treatment rather than to other fac-
tors that cause chronic kidney disease in the general
population.
A critical question (Werneke et al. 2010) is when to
stop lithium in a patient who develops impairment in
kidney function. Such a decision should not be based
exclusively on whether a patient has a slowly increasing
creatinine. Two key factors may help guide the decision
to stop lithium: 1) Whether the past treatment history
or family histories suggest that it is possible to switch
the patient to an alternative therapy without significantly
increasing the risk of relapse or suicide. If the patient is
a good responder to lithium and cessation of lithium will
drastically increase the risk of affective deterioration,
then the therapeutic efficacy of lithium may outweigh
the risk of nephrotoxicity. If another therapy known to
be effective in this patient is available, lithium cessation
should be considered. However, it should be noted that
other mood stabilizer medications also have serious side
effects and are not necessarily safer than lithium. 2)
Whether cessation of lithium will avoid further dete-
rioration in kidney function. If assessment of kidney
function suggests reversible damage and possibility of
stabilization or improvement, then it is reasonable to
consider stopping lithium. In most patients it is impos-
sible to predict whether discontinuation of lithium will
result in stabilization of kidney function. If the renal im-
pairment is irreversible, discontinuation of lithium will
not benefit the kidneys but may increase the risk of re-
lapse and thus should be avoided. NDI, even when se-
vere, or increase in creatinine levels or decrease in
creatinine clearance, is almost never an indication for
abrupt lithium discontinuation. There is no medical
emergency and discontinuation if decided upon can be
very gradual with overlap of alternative therapy.
New mood stabilizers that are alternatives to the use
of lithium first came into the field from the anticonvulsantworld where valproate, carbamazepine, and lamotrigine all
seem to have mood-stabilizing properties. More recently,
the atypical antipsychotics including olanzapine, quetia-
pine, aripiprizole, and lurasidone (Belmaker 2014) have all
been shown to prevent manias and depressions. None of
these agents show overall superiority to lithium although
lithium is not overall superior to these alternatives. Each
alternative presents its own unique and serious side effect
profile. Despite the fact that lithium is an unpatented
compound and that newer patented compounds have
been marketed vigorously, psychiatrists in the developed
world seem to continue to prescribe lithium to a signifi-
cant fraction of bipolar patients. This may be because
some difficult-to-define subgroup of bipolar patients is
particularly responsive to lithium or because the side ef-
fect profile of lithium is more acceptable to some patients.
The mechanism of action of lithium is unique among the
mood stabilizers since it is neither an anticonvulsant nor a
dopamine D2 blocker. Its mechanism of action is not
known but it has major effects on inositol monophospha-
tase and glycogen synthase kinase (Toker et al. 2014).
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